Drug Trial Radar · NCT04824079
Keynatinib in Treated Patients With NSCLC and Brain Metastases
Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Oct 21, 2020
Primary completion
Dec 10, 2024
Study completion Dec 10, 2024
Sponsor
- Lead sponsor
- Medolution Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or progression of brain metastasis after treatment with EGFR inhibitors. As well as, to evaluate the penetration rate of Keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics, and the relationship between exposure levels with efficacy and safety.
Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation
- Brain Metastases
Interventions
KeynatinibDrug
The recommended dose is 20 mg Keynatinib twice a day until disease progression, unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: From start of treatment to time of progression (in CNS or non-CNS disease) , intolerable toxicity, withdrawal of informed consent or death, whichever occurs first,assessed up to 2 years.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Shandong Cancer Hospital
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.